Ameliorating the antimicrobial resistance crisis: phage therapy

Saha, Dibya; Mukherjee, Raju

doi:10.1002/iub.2010

Cited by 35 publications

(31 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The bacteriophages isolated and tested in this study were able to significantly reduce the A. hydrophila biofilm mass after 24 h of treatment. While these bacteriophages as well as others are active against biofilms (Hansen et al, 2019;Saha and Mukherjee, 2019), the factors associated with their efficacy have not been fully elucidated. The bacteriophages isolated in this study were diverse in morphology, genome content and organization.…”

Section: Discussionmentioning

confidence: 99%

Novel Bacteriophages Capable of Disrupting Biofilms From Clinical Strains of Aeromonas hydrophila

et al. 2020

View full text Add to dashboard Cite

The increase in global warming has favored growth of a range of opportunistic environmental bacteria and allowed some of these to become more pathogenic to humans. Aeromonas hydrophila is one such organism. Surviving in moist conditions in temperate climates, these bacteria have been associated with a range of diseases in humans, and in systemic infections can cause mortality in up to 46% of cases. Their capacity to form biofilms, carry antibiotic resistance mechanisms, and survive disinfection, has meant that they are not easily treated with traditional methods. Bacteriophage offer a possible alternative approach for controlling their growth. This study is the first to report the isolation and characterization of bacteriophages lytic against clinical strains of A. hydrophila which carry intrinsic antibiotic resistance genes. Functionally, these novel bacteriophages were shown to be capable of disrupting biofilms caused by clinical isolates of A. hydrophila. The potential exists for these to be tested in clinical and environmental settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Bacteriophages Capable of Disrupting Biofilms From Clinical Strains of Aeromonas hydrophila

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It should, however, be noted that some phages are able to transfer bacterial genes by transduction, a factor that must be taken into consideration during the early stage of phage selection. A comprehensive analysis of theoretical advantages of phages over antibiotics, together with some of their limitations, has been reviewed [117,118] including the degree of synergy with antibiotics. However, phage-bacterial co-evolution is of immediate practical significance to phage therapy in the development of bacterial resistance to the phage during treatment.…”

Section: What Can We Learn From Approved Viral Therapies; Bacterial Vmentioning

confidence: 99%

Viruses of protozoan parasites and viral therapy: Is the time now right?

Barrow

Dujardin

Fasel

et al. 2020

Virol J

View full text Add to dashboard Cite

Infections caused by protozoan parasites burden the world with huge costs in terms of human and animal health. Most parasitic diseases caused by protozoans are neglected, particularly those associated with poverty and tropical countries, but the paucity of drug treatments and vaccines combined with increasing problems of drug resistance are becoming major concerns for their control and eradication. In this climate, the discovery/repurposing of new drugs and increasing effort in vaccine development should be supplemented with an exploration of new alternative/synergic treatment strategies. Viruses, either native or engineered, have been employed successfully as highly effective and selective therapeutic approaches to treat cancer (oncolytic viruses) and antibiotic-resistant bacterial diseases (phage therapy). Increasing evidence is accumulating that many protozoan, but also helminth, parasites harbour a range of different classes of viruses that are mostly absent from humans. Although some of these viruses appear to have no effect on their parasite hosts, others either have a clear direct negative impact on the parasite or may, in fact, contribute to the virulence of parasites for humans. This review will focus mainly on the viruses identified in protozoan parasites that are of medical importance. Inspired and informed by the experience gained from the application of oncolytic virus- and phage-therapy, rationally-driven strategies to employ these viruses successfully against parasitic diseases will be presented and discussed in the light of the current knowledge of the virus biology and the complex interplay between the viruses, the parasite hosts and the human host. We also highlight knowledge gaps that should be addressed to advance the potential of virotherapy against parasitic diseases.

show abstract

“…However，some pathogenic bacteria such as P aeruginosa and Clostridioides harbor CRISPR‐Cas systems, which prevent phage propagation and lysis in host bacterial cells . Engineered phages that contain Acrs could help phage therapy overcome this limitation …”

Section: Acr Mechanismsmentioning

confidence: 99%

Anti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems

Zhang

Song

Tian

2019

Anim Models and Exp Med

View full text Add to dashboard Cite

CRISPR (clustered regularly interspaced short palindromic repeats)‐Cas (CRISPR associated protein) systems serve as the adaptive immune system by which prokaryotes defend themselves against phages. It has also been developed into a series of powerful gene‐editing tools. As the natural inhibitors of CRISPR‐Cas systems, anti‐CRISPRs (Acrs) can be used as the “off‐switch” for CRISPR‐Cas systems to limit the off‐target effects caused by Cas9. Since the discovery of CRISPR‐Cas systems, much research has focused on the identification, mechanisms and applications of Acrs. In light of the rapid development and scientific significance of this field, this review summarizes the history and research status of Acrs, and considers future applications.

show abstract

Ameliorating the antimicrobial resistance crisis: phage therapy

Cited by 35 publications

References 108 publications

Novel Bacteriophages Capable of Disrupting Biofilms From Clinical Strains of Aeromonas hydrophila

Novel Bacteriophages Capable of Disrupting Biofilms From Clinical Strains of Aeromonas hydrophila

Viruses of protozoan parasites and viral therapy: Is the time now right?

Anti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems

Contact Info

Product

Resources

About